Scientific Reports (Mar 2023)

Analytical and clinical validity of wearable, multi-sensor technology for assessment of motor function in patients with Parkinson’s disease in Japan

  • Genko Oyama,
  • Maximilien Burq,
  • Taku Hatano,
  • William J. Marks,
  • Ritu Kapur,
  • Jovelle Fernandez,
  • Keita Fujikawa,
  • Yoshihiko Furusawa,
  • Keisuke Nakatome,
  • Erin Rainaldi,
  • Chen Chen,
  • King Chung Ho,
  • Takashi Ogawa,
  • Hikaru Kamo,
  • Yutaka Oji,
  • Haruka Takeshige-Amano,
  • Daisuke Taniguchi,
  • Ryota Nakamura,
  • Fuyuko Sasaki,
  • Shinichi Ueno,
  • Kenta Shiina,
  • Anri Hattori,
  • Noriko Nishikawa,
  • Mayu Ishiguro,
  • Shinji Saiki,
  • Ayako Hayashi,
  • Masatoshi Motohashi,
  • Nobutaka Hattori

DOI
https://doi.org/10.1038/s41598-023-29382-6
Journal volume & issue
Vol. 13, no. 1
pp. 1 – 13

Abstract

Read online

Abstract Continuous, objective monitoring of motor signs and symptoms may help improve tracking of disease progression and treatment response in Parkinson’s disease (PD). This study assessed the analytical and clinical validity of multi-sensor smartwatch measurements in hospitalized and home-based settings (96 patients with PD; mean wear time 19 h/day) using a twice-daily virtual motor examination (VME) at times representing medication OFF/ON states. Digital measurement performance was better during inpatient clinical assessments for composite V-scores than single-sensor–derived features for bradykinesia (Spearman |r|= 0.63, reliability = 0.72), tremor (|r|= 0.41, reliability = 0.65), and overall motor features (|r|= 0.70, reliability = 0.67). Composite levodopa effect sizes during hospitalization were 0.51–1.44 for clinical assessments and 0.56–1.37 for VMEs. Reliability of digital measurements during home-based VMEs was 0.62–0.80 for scores derived from weekly averages and 0.24–0.66 for daily measurements. These results show that unsupervised digital measurements of motor features with wrist-worn sensors are sensitive to medication state and are reliable in naturalistic settings. Trial Registration: Japan Pharmaceutical Information Center Clinical Trials Information (JAPIC-CTI): JapicCTI-194825; Registered June 25, 2019.